The Top Line What were the biggest clinical trial flops of 2024?
Feb 21, 2025
James Waldron, a journalist from Fierce Biotech, brings insights on the biggest clinical trial failures of 2024. He highlights the disappointing results from major companies like AbbVie and Pfizer, particularly in trials for schizophrenia and Duchenne muscular dystrophy. The discussion delves into lessons learned from these setbacks and the human impact of failed trials. Waldron and Gabrielle Masson also explore the ongoing challenges the industry faces and the crucial need for innovative treatments to improve patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
AbbVie's Schizophrenia Setback
- AbbVie's schizophrenia drug, acquired for $8.7B, failed trials.
- This highlights the high-risk nature of drug development, especially in challenging therapeutic areas.
Merck's Anti-TIGIT Drug Failure
- Merck's anti-TIGIT drug, vivostolumab, faced setbacks and eventual discontinuation.
- This reflects broader challenges for anti-TIGIT drugs in immuno-oncology.
Roche's Mixed Results with TIGIT
- Roche's TIGIT drug, tiragolumab, showed initial promise but later failed trials.
- The future of TIGIT drugs remains uncertain despite Roche's early success.